Table 2.
Regression analysis for the primary outcomes.
| Outcomes | Crude analysis |
P-valueb | Hazard Ratio (HR) (95% CI) | P-valuec | |
|---|---|---|---|---|---|
| Single-dose | Multiple-dose | ||||
| 30-day mortality, n (%)a | 24/64 (37.5) | 22/64 (34.4) | 0.71 | 0.79 (0.43, 1.45) | 0.44 |
| In hospital mortality, n (%)a | 26/64 (40.6) | 23/60 (38.3) | 0.79 | 0.81 (0.46, 1.49) | 0.53 |
a
Denominator of the percentage is the total number of patients.
b
Chi-square test is used to calculate the P-value.
c
Propensity score matching based on patient's baseline severity score (i.e., APACHE II), Best GCS, INR, albumin, MV status within 24 h of ICU admission and the use of pharmacological DVT prophylaxis to calculate hazard ratio and p-value.